What is going on with natural killer cells in HIV infection?

International Archives of Allergy and Immunology

Volumn 133, Issue 4, 2004, Pages 330-339

  Dines, Ilana ^a   Rumjanek, Vivian M ^a   Persechini, Pedro Muanis ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Acquired immunodeficiency syndrome; Human immunodeficiency virus; Natural killer cells; Perforin

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; PERFORIN; PROTEINASE INHIBITOR;

CELL ACTIVITY; CELL COUNT; CELL DEATH; CELL FUNCTION; CELL SUBPOPULATION; CYTOKINE RELEASE; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; INHIBITION KINETICS; MOLECULAR MECHANICS; NATURAL KILLER CELL; PATHOGENESIS; PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VIRUS LOAD;

CYTOTOXICITY, IMMUNOLOGIC; HIV; HIV INFECTIONS; HUMANS; KILLER CELLS, NATURAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1842851832     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077352     Document Type: Review

References (167)

1. Gallo RC, Sarngadharan MG, Popovic M, et al: HTLV-III and the etiology of AIDS. Prog Allergy 1986;37:1-45.
2. Montagnier L: Lymphadenopathy associated virus: Its role in the pathogenesis of AIDS and related diseases. Prog Allergy 1986;37:46-64.
3. Rosenberg ZF, Fauci AS: The immunopathogenesis of HIV infection. Adv Immunol 1989;47:377-341.
4. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
5. McMichael AJ, Phillips RE: Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997;15:271-296.
6. Fauci AS: Multifactorial nature of human immunodeficiency virus disease - Implications for therapy. Science 1993;262:1011-1018.
7. Weiss RA: How does HIV cause AIDS? Science 1993;260:1273-1279.
8. Levy JA: HIV pathogenesis and long-term survival. AIDS 1993;7:1401-1410.
9. Crowe SM, Kornbluth RS: Overview of HIV interactions with macrophages and dendritic cells: The other infection in AIDS. J Leukoc Biol 1994;56:215-217.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
11. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
12. Safrit JT, Koup RA: The immunology of primary HIV infection: Which immune responses control HIV replication? Curr Opin Immunol 1995;7:456-461.
13. De Maria A, Ferraris A, Guastella M, et al: Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: Impairment of specific cytolytic functions. Proc Natl Acad Sci USA 1997;94:10285-10288.
14. Appay V, Nixon DF, Donahoe SM, et al: HIVspecific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
15. Ortaldo JR, Mathieson BJ, Wiltrout RH: Characterization and functions of natural killer cells. Ann Inst Pasteur Immunol 1988;139:444-450.
16. Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-2438.
17. Welsh RM, Brubaker JO, Vargas-Cortes M, O'Donnell CL: Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J Exp Med 1991;173:1053-1063.
18. Bellone G, Valiante NM, Viale O, Ciccone E, Moretta L, Trinchieri G: Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones. J Exp Med 1993;177:1117-1125.
19. Scott P, Trinchieri G: The role of natural killer cells in host-parasite interactions. Curr Opin Immunol 1995;7:34-40.
20. Moretta A: Molecular mechanisms in cell-mediated cytotoxicity. Cell 1997;90:13-18.
21. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G: Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998;161:5821-5824.
22. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187-376.
23. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4486.
24. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH: Molecular and functional analysis of human natural killer cellassociated neural cell adhesion molecule (NCAM/CD56). J Immunol 1991;146:4421-4426.
25. Reynolds CW, Ortaldo JR: Natural killer activity: The definition of a function rather than a cell type. Immunol Today 1987;8:172-174.
26. Lanier LL, Phillips JH: Evidence for three types of human cytotoxic lymphocyte. Immunol Today 1986;7:132-134.
27. Ortaldo JR, Winkler-Pickett RT, Yagita H, Young HA: Comparative studies of CD3- and CD3+ CD56+ cells: Examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991;136:486-495.
28. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921-930.
29. Kägi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996;14:207-232.
30. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
31. Hidore RM, Nabavi N, Sonleitner F, Murphy WJ: Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun 1991;59:1747-1754.
32. Ratcliffe LT, Lukey PT, Mackenzie CR, Ress SR: Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis. Clin Exp Immunol 1994;97:373-379.
33. Altare F, Durandy A, Lammas D, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-1435.
34. Kärre K, Hansson M, Kiessling R: Multiple interactions at the natural killer workshop. Immunol Today 1991;12:343-345.
35. Feuer G, Stewart SA, Baird SM, Lee F, Feuer R, Chen ISY: Potential role of natural killer cells in controlling tumorigenesis by human Tcell leukemia viruses. J Virol 1995;69:1328-1333.
36. Smyth MJ, Thia KY, Street SE, et al: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
37. Asai O, Longo DL, Tian ZG, et al: Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998;101:1835-1842.
38. Davenport C, Kumar V, Bennett M: Rapid rejection of H2(k) and H2(k/b) bone marrow cell grafts by CD8(+) T cells and NK cells in irradiated mice. J Immunol 1995;155:3742-3749.
39. Liu C-C, Young LHY, Young JDE: Lymphocyte-mediated cytolysis and disease. N Engl J Med 1996;335:1651-1659.
40. Herberman RB, Ortaldo JR: Nautral killer cells: Their role in defenses against disease. Science 1981;214:24-30.
41. King A, Loke YW, Chaouat G: NK cells and reproduction. Immunol Today 1997;18:64-66.
42. Pazmany L, Mandelboim O, Valesgomez M, Davis DM, Reyburn HT, Strominger JL: Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996;274:792-795.
43. King A, Wooding P, Gardner L, Loke YW: Expression of perforin, granzyme-A and TIA-1 by human uterine CD56+ NK cells implies they are activated and capable of effector functions. Hum Reprod 1993;8:2061-2067.
44. Masson D, Tschopp J: Isolation of a lytic, poreforming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem 1985;260:9069-9072.
45. Tschopp J, Conzelmann A: Proteoglycans in secretory granules of NK cells. Immunol Today 1986;7:135-136.
46. Masson D, Nabholz M, Estrade C, Tschopp J: Granules of cytolytic T-lymphocytes contain two serine esterases. EMBO J 1986;5:1595-1600.
47. Pena SV, Krensky AM: Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Semin Immunol 1997;9:117-125.
48. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and fas lytic pathways. Nature 1994;370:650-652.
49. Benz R, Janko K, Boos W, Lauger P: Formation of large, ion-permeable membrane channels by the matrix protein (porin) of Escherichia coli. Biochim Biophys Acta 1978;511:305-319.
50. Podack ER, Young JDE, Cohn ZA: Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA 1985;82:8629-8633.
51. Young JDE, Hengartner H, Podack ER, Cohn ZA: Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell 1986;44:849-859.
52. Podack ER, Hengartner H, Lichtenheld MG: A central role of perforin in cytolysis? Annu Rev Immunol 1991;9:129-157.
53. Young JDE, Cohn ZA, Podack ER: The ninth component of complement and the pore-forming protein (Perforin 1) from cytotoxic T cells: Structural, immunological, and functional similarities. Science 1986;233:184-190.
54. Zalman LS, Brothers MA, Chiu FJ, Muller-Eberhard HJ: Mechanism of cytotoxicity of human large granular lymphocytes: Relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci USA 1986;83:5262-5266.
55. Shi L, Mai S, Israels S, Browne K, Trapani JA, Greenberg AH: Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med 1997;185:855-866.
56. Pinkoski MJ, Hobman M, Heibein JA, et al: Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. Blood 1998;92:1044-1054.
57. Trapani JA, Jans P, Smyth MJ, et al: Perforindependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ 1998;5:488-496.
58. Spaner D, Raju K, Radvanyi L, Lin Y, Miller RG: A role for perforin in activation-induced cell death. J Immunol 1998;160:2655-2664.
59. Stepp SE, Mathew PA, Bennett M, de Saint B, Kumar V: Perforin: More than just an effector molecule. Immunol Today 2000;21:254-256.
60. Bluman EM, Bartynski KJ, Avalos BR, Caligiuri MA: Human natural killer cells produce abundant macrophage inflammatory protein-1 in response to monocyte-derived cytokines. J Clin Invest 1996;97:2722-2727.
61. Loetscher P, Seitz M, Clarklewis I, Baggiolini M, Moser B: Activation of NK cells by CC chemokines - Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 1996;156:322-327.
62. Wagner L, Yang OO, Garcia-Zepeda EA, et al: Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998;391:908-911.
63. Levy JA: Infection by human immunodeficiency virus - CD4 is not enough. N Engl J Med 1996;335:1528-1530.
64. Deng H, Liu R, Ellmeier W, et al: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
65. Bleul CC, Farzan M, Choe H, et al: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-833.
66. Fehniger TA, Herbein G, Yu H, et al: Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998;161:6433-6438.
67. Oliva A, Kinter AL, Vaccarezza M, et al: Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-231.
68. Kottilil S, Chun TW, Moir S, et al: Innate immunity in human immunodeficiency virus infection: Effect of viremia on natural killer cell function. J Infect Dis 2003;187:1038-1045.
69. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigenspecific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
70. Scharton TM, Scott P: Natural killer cells are a source of interferon τ that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-577.
71. Pileri P, Uematsu Y, Campagnoli S, et al: Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
72. Tseng CT, Klimpel GR: Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-49.
73. Crotta S, Stilla A, Wack A, et al: Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002;195:35-41.
74. Chehimi J, Bandyopadhyay S, Prakash K, et al: In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates. J Virol 1991;65:1812-1822.
75. Scott-Algara D, Vuillier F, Cayota A, et al: In vitro non-productive infection of purified natural killer cells by the BRU isolate of the human immunodeficiency virus type 1. J Gen Virol 1993;74:725-731.
76. Valentin A, Rosati M, Patenaude DJ, et al: Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-7020.
77. Creemers PC, Stark DF, Boyko WJ: Evaluation of natural killer cell activity in patients with persistent generalized lymphadenopathy and acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1985;36:141-150.
78. Landay A, Ohlsson-Wilhelm B, Giorgi JV: Application of flow cytometry to the study of HIV infection. AIDS 1990;4:479-497.
79. Bonavida B, Katz J, Gottlieb M: Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells and partial restoration by IL-2. J Immunol 1986;137:1157-1163.
80. Brenner BG, Dascal A, Margolese RG, Wainberg MA: Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol 1989;46:75-83.
81. Cai Q, Huang X-L, Rappocciolo G, Rinaldo CR Jr: Natural killer cell responses in homosexual men with early HIV infection. J AIDS 1990;3:669-676.
82. Margolick BJ, Scott RE, Odaka N, Saah JA: Flow cytometric analysis of gamma delta T cells and natural killer cells in HIV-1 infection. Clin Immunol Immunopathol 1991;58:126-138.
83. Brenner BG, Gryllis C, Gornitsky M, Wainberg MA: Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol 1993;93:142-148.
84. Sirianni MC, Mezzaroma I, Aiuti F, Moretta A: Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody. Eur J Immunol 1994;24:1874-1878.
85. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, Pedersen BK: Defective natural immunity: An early manifestation of human immunodeficiency virus infection. J Exp Med 1995;182:789-799.
86. World Health Organization: Acquired Immunodeficiency Syndrome (AIDS): Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990;65:221-228.
87. Havlir DV, Richman DD: Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-994.
88. Carpenter CC, Cooper DA, Fischl MA, et al: Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
89. Ullum H, Katzenstein T, Aladdin H, et al: Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Scand J Immunol 1999;49:539-547.
90. Weber K, Meyer D, Grosse V, Stoll M, Schmidt RE, Heiken H: Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 2000;202:172-178.
91. Douglas SD, Durako SJ, Tustin NB, et al: Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses 2001;17:543-552.
92. Azzoni L, Papasavvas E, Chehimi J, et al: Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol 2002;168:5764-5770.
93. Brogan M, Targan S: Evidence for involvement of serine proteases in the late stages of the natural killer cell lytic reaction. Cell Immunol 1986;103:426-433.
94. Clément M-V, Haddad P, Soulié A, et al: Involvement of granzyme B and perforin gene expression in the lytic potential of human natural killer cells. Res Immunol 1990;141:477-489.
95. Hu PF, Hultin LE, Hultin P, et al: Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16(+)CD56(+) cells and expansion of a population of CD16(dim)CD56(-) cells with low lytic activity. J AIDS Hum Retrovirol 1995;10:331-340.
96. Lucia B, Jennings C, Cauda R, Ortona L, Landay AL: Evidence of a selective depletion of a CD16(+) CD56(+) CD8(+) natural killer cell subset during HIV infection. Cytometry 1995;22:10-15.
97. Wallace PK, Howell AL, Fanger MW: Role of Fc τ receptors in cancer and infectious disease. J Leukoc Biol 1994;55:816-826.
98. Brenner BG, Gryllis C, Wainberg MA: Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991;50:628-640.
99. Ahmad A, Morisset R, Thomas R, Menezes J: Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J AIDS 1994;7:428-437.
100. Forthal DN, Landucci G, Daar ES: Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001;75:6953-6961.
101. Ahmad R, Sindhu ST, Toma E, et al: Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001;21:227-233.
102. Ahmad A, Menezes J: Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996;10:258-266.
103. Weinhold KJ: Anti-HIV-1 ADCC: Clinical and therapeutic implications. Biotechnol Ther 1991;2:147-157.
104. Ahmad A, Menezes J: Positive correlation between the natural killer and gp120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J AIDS Hum Retrovirol 1995;10:115-119.
105. Sadatsowti B, Debre P, Mollet L, et al: An inhibitor of cytotoxic functions produced by CD8(+)CD57(+) T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol 1994;24:2882-2888.
106. Goicoa MA, Sen L, Iannitelli PS, Diez RA, Estevez ME: Natural killer suppressor factors in sera from HIV-infected subjects. Scand J Immunol 1995;41:523-528.
107. Peruzzi M, Azzari C, Rossi ME, De Martino M, Vierucci A: Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide. AIDS Res Hum Retroviruses 2000;16:1067-1073.
108. Harris DT, Cianciolo GJ, Snyderman R, Argov S, Koren HS: Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. J Immunol 1987;138:889-894.
109. Muller C, Kukel S, Bauer R: Antibodies to natural killer cells in HIV-infected patients. AIDS 1993;7:291-292.
110. Muller C, Szangolies M, Kukel S, et al: Characterization of autoantibodies to natural killer cells in HIV-infected patients. Scand J Immunol 1996;43:583-592.
111. O'Dorisio MS, Wood CL, O'Dorisio TM: Vasoactive intestinal peptide and neuropeptide modulation of the immune response. J Immunol 1985;135:792s-796s.
112. Rola-Pleszczynski M, Bolduc D, St-Pierre S: The effects of vasoactive intestinal peptide on human natural killer cell function. J Immunol 1985;135:2569-2573.
113. Ottaway CA: Vasoactive intestinal peptide as a modulator of lymphocyte and immune function. Ann NY Acad Sci 1988;527:486-500.
114. Pozo D, Delgado M, Martinez M, et al: Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000;21:7-11.
115. Bonavida B, Wright SC: Role of natural killer cytotoxic factors in the mechanism of targetcell killing by natural killer cells. J Clin Immunol 1986;6:1-8.
116. Sirianni MC, Soddus S, Malorni W, Arancia G, Aiuti F: Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin. J Immunol 1988;140:2565-2568.
117. Di Pietro A, Dayan G, Conseil G, et al: Pglycoprotein-mediated resistance to chemotherapy in cancer cells: Using recombinant cytosolic domains to establish structure-function relationships. Braz J Med Biol Res 1999;32:925-939.
118. Wadkins RM, Roepe PD: Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Int Rev Cytol 1997;171:121-165.
119. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-2458.
120. Lucia MB, Cauda R, Malorni W, et al: P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunol Lett 1995;47:223-226.
121. Malorni W, Lucia MB, Rainaldi G, et al: Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 1998;83:13-20.
122. Cauda R, Lucia MB, Ortona L, Rainaldi G, Donelli G, Malorni W: A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. Immunol Lett 1998;60:19-21.
123. N'cho M, Hobbs JA, Brahmi Z: Over-expression of multidrug resistance P-glycoprotein inhibits NK granule-mediated lytic ability without affecting the Fas lytic pathway. Hum Immunol 1999;60:223-230.
124. Portales P, Reynes J, Pinet V, et al: Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS 2003;17:495-504.
125. Cambiaggi A, Vivier E, Olcese L: Inhibitory and activatory receptors for MHC class I molecules. Res Immunol 1997;148:172-179.
126. Cantoni C, Biassoni R: HLA class-I-specific NK receptors belong to two distinct molecular families and display inhibitory or activating function. Res Immunol 1997;148:146-150.
127. Lanier LL: Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 1999;92:705-707.
128. Lanier LL: NK cell receptors. Annu Rev Immunol 1998;16:359-393.
129. Galiani MD, Aguado E, Tarazona R, et al: Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals. Clin Exp Immunol 1999;115:472-476.
130. Andre P, Brunet C, Guia S, et al: Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimmers on NK and T lymphocytes from HIV-1-infected individuals. Eur J Immunol 1999;29:1076-1085.
131. Cohen GB, Gandhi RT, Davis DM, et al: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-671.
132. Collins KL, Baltimore D: HIV's evasion of the cellular immune response. Immunol Rev 1999;168:65-74.
133. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725-3729.
134. Valiante NM, Rengaraju M, Trinchieri G: Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B-cell lines to stimulate T-cell and NKcell proliferation. Cell Immunol 1992;145:187-198.
135. Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B: Definition of a natural killer NKR-P1A(+)/CD56(-)/CD16(-) functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J Exp Med 1996;184:1845-1856.
136. Puzanov IJ, Williams NS, Schatzle J, Sivakumar PV, Bennett M, Kumar V: Ontogeny of NK cells and the bone marrow microenvironment: Where does IL15 fit in? Res Immunol 1997;148:195-201.
137. Liu C-C, Perussia B, Young JDE: The emerging role of IL-15 in NK-cell development. Immunol Today 2000;21:113-116.
138. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G: Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12): Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992;148:92-98.
139. Romagnani S: Induction of TH1 and TH2 responses - A key role for the natural immune response. Immunol Today 1992;13:379-381.
140. H1 cells. Immunol Today 1993;14:335-338.
141. De Sanctis JB, Blanca I, Bianco NE: Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins. Immunology 1997;90:526-533.
142. Trinchieri G: Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol 1997;9:17-23.
143. Clerici M, Shearer GM: A T(H)1->1T(H)2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-110.
144. Chehimi J, Starr SE, Frank I, et al: Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175:789-796.
145. Chehimi J, Valiante NM, Dandrea A, et al: Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol 1993;23:1826-1830.
146. Deblakerhohe DF, Yamauchi A, Yu CR, Horvatharcidiacono JA, Bloom ET: IL-12 synergizes with IL-2 to induce lymphokineactivated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 1995;165:33-43.
147. Rodella L, Rezzani R, Zauli G, Mariani AR, Rizzoli R, Vitale M: Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. Int Immunol 1998;10:719-725.
148. Nguyen QH, Roberts RL, Ank BJ, Lin SJ, Thomas EK, Stiehm ER: Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells. Cell Immunol 1998;185:83-92.
149. Naora H, Gougeon ML: Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15. Immunol Lett 1999;68:359-367.
150. Perera LP, Goldman CK, Waldmann TA: IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J Immunol 1999;162:2606-2612.
151. Dandrea A, Asteamezaga M, Valiante NM, Ma XJ, Kubin M, Trinchieri G: Interleukin-10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
152. De Waal M, Abrams J, Bennett B, Figdor CG, De Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
153. Carson WE, Lindemann MJ, Baiocchi R, et al: The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995;85:3577-3585.
154. Parato KG, Kumar A, Badley AD, et al: Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS 2002;16:1251-1256.
155. Lanier LL: Natural killer cells: From no receptors to too many. Immunity 1997;6:371-378.
156. Maggi E, Mazzetti M, Ravina A, et al: Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994;265:244-248.
157. Graziosi C, Pantaleo G, Gantt KR, et al: Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 1994;265:248-252.
158. Duarte AJS, Hong MA, Camargo LS, et al: Cytokine profile and natural killer activity among Brazilian HIV-1-infected subjects. Mem Inst Oswaldo Cruz 1998;93:403-404.
159. Chehimi J, Starr SE, Frank I, et al: Impaired interleukin-12 production in human immunodeficiency virus-infected patients. J Exp Med 1994;179:1361-1366.
160. Marshall JD, Chehimi J, Gri G, Kostman JR, Montaner LJ, Trinchieri G: The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Blood 1999;94:1003-1011.
161. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA: Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type-1 infection. J Exp Med 1993;177:483-492.
162. Khatri VP, Fehniger TA, Baiocchi RA, et al: Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest 1998;101:1373-1378.
163. Smith KA: Low-dose daily interleukin-2 immunotherapy: Accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 2001;15(suppl 2):S28-S35.
164. Mitsuyasu RT: The potential role of interleukin-2 in HIV. AIDS 2001;15(suppl 2):S22-S27.
165. Trinchieri G, Scott P: The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994;15:460-463.
166. Chehimi J, Paganin C, Frank I, Chouaib S, Starr S, Trinchieri G: Interleukin-12 in the pathogenesis and therapy of HIV disease. Res Immunol 1995;146:605-612.
167. Lin SJ, Roberts RL, Ank BJ, Nguyen QH, Thomas EK, Stiehm ER: Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. J Clin Immunol 1998;18:335-345.